In Brief: Immunomedics' CEA-Scan
Executive Summary
Immunomedics' CEA-Scan: Receives "approvable" status at FDA April 9. The colorectal cancer diagnostic imaging product will be marketed in the U.S. by the Mallinckrodt Group under an agreement announced April 9. Under terms of the agreement, Mallinckrodt will market, sell and distribute CEA-Scan on a consignment basis, while Immunomedics will retain manufacturing rights and will participate in marketing, including possible additional financing. Mallinckrodt Medical has European marketing rights under an agreement signed last year...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth